Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

ClinicalTrials.gov ID: NCT04166552

Public ClinicalTrials.gov record NCT04166552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).

Study identification

NCT ID
NCT04166552
Recruitment status
Suspended
Study type
Interventional
Phase
Phase 2
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Enrollment
36 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 74 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2020
Primary completion
Jun 30, 2024
Completion
Sep 30, 2024
Last update posted
Sep 20, 2023

2020 – 2024

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
Arizona Arthritis & Rheumatology Associates, P.C. Phoenix Arizona 85032
Care Access Research - Huntington Huntington Beach California 92648
Pacific Arthritis Care Center Los Angeles California 90045
UCLA Division of Rheumatology Los Angeles California 90095
Inland Rheumatology Clinical Trials Upland California 91786
Yale University New Haven Connecticut 06511
Central Florida Pulmonary Group Altamonte Springs Florida 32701
Life Clinical Trials Margate Florida 33063
Novel Clinical Research Center Miami Florida 33186
Northwestern University Chicago Illinois 60208
University of Minnesota Minneapolis Minnesota 55455
Rutgers, The State University of New Jersey New Brunswick New Jersey 08901
Cleveland Clinic Cleveland Ohio 44195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04166552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 20, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04166552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →